Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma

被引：0
|
作者：
John P. Fruehauf
Monica El-Masry
Katherine Osann
Basmina Parmakhtiar
Maki Yamamoto
James G. Jakowatz
机构：
[1] University of California,Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center
[2] University of California,Division of Surgical Oncology, Chao Family Comprehensive Cancer Center
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词：
Pazopanib; Metronomic paclitaxel; Metastatic melanoma; Antiangiogenic agent; BRAF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 360
页数：7
相关论文
共 50 条
  • [1] Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
    Fruehauf, John P.
    El-Masry, Monica
    Osann, Katherine
    Parmakhtiar, Basmina
    Yamamoto, Maki
    Jakowatz, James G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 353 - 360
  • [2] Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer
    Narayanan, Sujata
    Lam, Anthony
    Vaishampayan, Ulka
    Harshman, Lauren
    Fan, Alice
    Pachynski, Russell
    Poushnejad, Shermeen
    Haas, Denise
    Li, Shufeng
    Srinivas, Sandy
    CLINICAL GENITOURINARY CANCER, 2016, 14 (05) : 432 - 437
  • [3] Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma
    Kim, K. B.
    Davies, M. A.
    Papadopoulos, N. E.
    Bedikian, A. Y.
    Hwu, W.
    Woodard, K.
    Washington, E. W.
    Dancey, J. E.
    Wright, J.
    Hwu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] A phase II study of pazopanib with oral topotecan in patients with metastatic osteosarcoma
    van Tine, B. A.
    Mohindra, N.
    Milhem, M.
    Attia, S.
    Robinson, S. I.
    Rademaker, A.
    Okuno, S. H.
    Agulnik, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] A phase II single-arm study of pazopanib and paclitaxel as first-line treatment for patients with advanced melanoma
    Fruehauf, John P.
    Alger, Beverly
    Jakowatz, James G.
    Hsiang, David
    Sender, Leonard S.
    Bettis, Claudette
    Casey, Cameron
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors
    Tan, Antoinette R.
    Dowlati, Afshin
    Jones, Suzanne F.
    Infante, Jeffrey R.
    Nishioka, Jennifer
    Fang, Lei
    Hodge, Jeffrey P.
    Gainer, Shelby D.
    Arumugham, Thangam
    Suttle, A. Benjamin
    Dar, Mohammed M.
    Lager, Joanne J.
    Burris, Howard A., III
    ONCOLOGIST, 2010, 15 (12): : 1253 - 1261
  • [7] A phase II study of REOLYSINA® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma
    Mahalingam, Devalingam
    Fountzilas, Christos
    Moseley, Jennifer
    Noronha, Nicole
    Tran, Hue
    Chakrabarty, Romit
    Selvaggi, Giovanni
    Coffey, Matthew
    Thompson, Brad
    Sarantopoulos, John
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 697 - 703
  • [8] A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma
    Devalingam Mahalingam
    Christos Fountzilas
    Jennifer Moseley
    Nicole Noronha
    Hue Tran
    Romit Chakrabarty
    Giovanni Selvaggi
    Matthew Coffey
    Brad Thompson
    John Sarantopoulos
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 697 - 703
  • [9] PHASE-II STUDY OF AMSA ALONE AND IN COMBINATION WITH DTIC IN PATIENTS WITH METASTATIC MELANOMA
    POLYZOS, A
    LEGHA, SS
    BURGESS, AM
    BENJAMIN, RS
    BODEY, GP
    INVESTIGATIONAL NEW DRUGS, 1988, 6 (01) : 57 - 61
  • [10] Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.
    Patel, Sapna Pradyuman
    Hwu, Wen-Jen
    Kim, Kevin B.
    Papadopoulos, Nicholas E.
    Hwu, Patrick
    Radvanyi, Laszlo George
    Mahoney, Sandy
    Deburr, Tawania L.
    Liu, Ping
    Bedikian, Agop Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345